A Prospective Multicenter Cohort Study on Surgical Treatment Strategies for Pediatric Mitral Regurgitation
Key facts
- Who runs it
- China National Center for Cardiovascular Diseases
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 427 people enrolled
- Started
- 18 Mar 2020
- Ended
- 20 Sept 2025
- Type of study
- Observational, 2 groups
- Treatments tested
- conventional mitral valve repair
- standardized mitral valve repair
- Record updated
- 16 December 2025
Who can take part
- Age
- Up to 14 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Age < 14 years
- No prior mitral valve surgery
- Preoperative echocardiography demonstrating moderate or severe mitral regurgitation
Who cannot take part
- Concomitant cardiac malformations unable to be corrected simultaneously
- Connective tissue disorders(e.g., Barlow's disease, Marfan syndrome)
- Moderate or severe mitral stenosis
- Ischemic mitral regurgitation
- Severe leaflet dysplasia precluding adequate coaptation
- Any type of cardiomyopathy
- Single ventricle physiology or common atrioventricular valve
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This prospective, multicenter cohort study aims to evaluate the outcomes of surgical repair for pediatric mitral regurgitation (MR) in China. From March 2020 to December 2024, consecutive patients younger than 14 years who underwent mitral valve repair at eight representative congenital heart disease centers were enrolled. Eligible patients were those with at least moderate MR on preoperative echocardiography and no prior mitral valve surgery. Patients with uncorrectable concomitant cardiac anomalies, moderate or greater mitral stenosis, ischemic MR, severe leaflet dysplasia, connective tissue disorders (e.g., Barlow, Marfan), cardiomyopathies, or single-ventricle physiology were excluded.
Read full original descriptionShow less
The primary endpoint is a composite of all-cause mortality, reoperation for cardiovascular causes, or recurrence of moderate-or-severe MR during follow-up. Secondary endpoints include perioperative outcomes such as postoperative hospital stay, intensive care unit stay, mechanical ventilation time, and hospitalization cost.
This study is designed to provide high-quality prospective evidence on the safety, durability, and predictors of surgical repair for pediatric MR in a contemporary, real-world, multicenter setting. The findings may inform surgical decision-making and postoperative management strategies for this rare but challenging population.
The 2 groups in the trial
- Conventional Group
Those who have undergone conventional mitral valve repair
Treatment: conventional mitral valve repair
- Standardized Group
Those who have undergone standardized mitral valve repair
Treatment: standardized mitral valve repair
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 December 2025